MX2022006631A - Dosificacion de un inhibidor de la tirosina cinasa de bruton. - Google Patents

Dosificacion de un inhibidor de la tirosina cinasa de bruton.

Info

Publication number
MX2022006631A
MX2022006631A MX2022006631A MX2022006631A MX2022006631A MX 2022006631 A MX2022006631 A MX 2022006631A MX 2022006631 A MX2022006631 A MX 2022006631A MX 2022006631 A MX2022006631 A MX 2022006631A MX 2022006631 A MX2022006631 A MX 2022006631A
Authority
MX
Mexico
Prior art keywords
bruton
dosing
tyrosine kinase
kinase inhibitor
methoxybenzamido
Prior art date
Application number
MX2022006631A
Other languages
English (en)
Inventor
Nisha Nanda
Donald Tsai
Barbara Jean Brandhuber
Nora Chien Yee Ku
Steven August Smith
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of MX2022006631A publication Critical patent/MX2022006631A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)

Abstract

La presente invención proporciona un método para administrar dosis del inhibidor de BTK, (S)-5- amino-3-(4-((5-fluoro-2-metoxib enzamido)metil)fenil)-1-(1,1,1-trifluoropropan-2-il)-1H-pirazol-4 - carboxamida o una sal farmacéuticamente aceptable del mismo para su uso en el tratamiento de afecciones tales como cáncer y enfermedades autoinmunitarias.
MX2022006631A 2019-12-06 2020-12-03 Dosificacion de un inhibidor de la tirosina cinasa de bruton. MX2022006631A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962944674P 2019-12-06 2019-12-06
US202063077996P 2020-09-14 2020-09-14
US202063109698P 2020-11-04 2020-11-04
PCT/US2020/063089 WO2021113497A1 (en) 2019-12-06 2020-12-03 Dosing of a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2022006631A true MX2022006631A (es) 2022-09-07

Family

ID=73854977

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006631A MX2022006631A (es) 2019-12-06 2020-12-03 Dosificacion de un inhibidor de la tirosina cinasa de bruton.

Country Status (11)

Country Link
US (1) US20230041515A1 (es)
EP (1) EP4069219A1 (es)
JP (2) JP7142173B2 (es)
KR (2) KR20220100992A (es)
CN (1) CN115175677A (es)
AU (2) AU2020397034B2 (es)
BR (1) BR112022009716A2 (es)
CA (1) CA3160417A1 (es)
IL (1) IL292882A (es)
MX (1) MX2022006631A (es)
WO (1) WO2021113497A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20220507A1 (es) 2015-12-16 2022-04-07 Loxo Oncology Inc Compuestos utiles como inhibidores de cinasa
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
EP4129999A1 (en) 2016-08-05 2023-02-08 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
PT3612531T (pt) 2017-04-18 2022-10-04 Shanghai Fochon Pharmaceutical Co Ltd Agentes indutores de apoptose
CN110869391A (zh) 2017-07-26 2020-03-06 豪夫迈·罗氏有限公司 用BET抑制剂,Bcl-2抑制剂和抗CD20抗体的组合疗法
JP2021510165A (ja) 2018-01-10 2021-04-15 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー ベンズアミド化合物
EP3788042A4 (en) 2018-04-29 2022-01-26 BeiGene, Ltd. BCL-2 INHIBITORS
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide

Also Published As

Publication number Publication date
JP2022518974A (ja) 2022-03-17
CN115175677A (zh) 2022-10-11
KR20230127372A (ko) 2023-08-31
WO2021113497A1 (en) 2021-06-10
EP4069219A1 (en) 2022-10-12
KR20220100992A (ko) 2022-07-18
US20230041515A1 (en) 2023-02-09
AU2024201263A1 (en) 2024-03-14
BR112022009716A2 (pt) 2022-08-09
AU2020397034B2 (en) 2023-12-07
JP7142173B2 (ja) 2022-09-26
AU2020397034A1 (en) 2022-07-21
CA3160417A1 (en) 2021-06-10
JP2022177119A (ja) 2022-11-30
IL292882A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
MX2021008342A (es) Derivados de pirazol como inhibidores de calicreina plasmatica.
TW201613644A (en) Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
EA202092154A1 (ru) Комбинированная терапия
MX2023001468A (es) Tratamiento de cancer de prostata.
MX2018014577A (es) Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b.
TN2017000158A1 (en) Carbazole derivatives
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
JOP20220092A1 (ar) جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
MX2021000094A (es) Compuesto de amino-pirimidina sustituido para usarse en un metodo para tratamiento y prevencion de esclerosis multiple.
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2022006631A (es) Dosificacion de un inhibidor de la tirosina cinasa de bruton.
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
HK1087638A1 (en) Use of tyrosine kinase inhibitors to treat diabetes
MX2019004822A (es) Derivado del pirazol 3,4-bipiridilo y metodo de preparacion del mismo y aplicacion medica del mismo.
MX2022001702A (es) Inhibidores de jak.
JOP20220104A1 (ar) نظام تجريع لعوامل مضادة لـ dll3
MX2022001159A (es) Nueva formulacion farmaceutica.
EA201990843A1 (ru) Лечение рака предстательной железы
MX2021005936A (es) Metodos farmaceuticos.
EA202190270A1 (ru) Способы лечения и профилактики рассеянного склероза с применением соединений замещенного аминопиримидина
BR112022005608A2 (pt) Inibidores de jak
PL426157A1 (pl) Zastosowanie medyczne 4-(2-fluorofenylo)-1-(4-metyloimidazol-5-ilo)tiosemikarbazydu